|
4D Molecular Therapeutics ، Inc. (FDMT) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
4D Molecular Therapeutics, Inc. (FDMT) Bundle
اكتشف الإمكانات الحقيقية لـ 4D Molecular Therapeutics ، Inc. (FDMT) مع حاسبة DCF المتقدمة! اضبط افتراضات المفتاح ، واستكشاف السيناريوهات المختلفة ، وقم بتقييم كيفية تأثير التغييرات على تقييم 4D Molecular Therapeutics ، Inc. (FDMT)-كل ذلك ضمن قالب Excel سهل الاستخدام.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.6 | 18.0 | 3.1 | 20.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 32.52 | -82.65 | 562.29 | -100 | -12.53 | -12.53 | -12.53 | -12.53 | -12.53 |
| EBITDA | -55.2 | -68.3 | -106.2 | -107.1 | -187.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -405.68 | -378.72 | -3392.52 | -516.9 | 100 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 1.4 | 3.0 | 3.9 | 5.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 10.6 | 16.74 | 124 | 27.74 | 100 | 51.02 | 51.02 | 51.02 | 51.02 | 51.02 |
| EBIT | -56.7 | -71.3 | -110.0 | -112.9 | -187.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -416.28 | -395.46 | -3516.52 | -544.65 | 100 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 276.7 | 315.4 | 218.6 | 288.2 | 424.9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 10.92 | 0.26056 | 0 | 0 | 100 | 22.24 | 22.24 | 22.24 | 22.24 | 22.24 |
| Inventories | .0 | -8.5 | -5.8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | -47.14 | -184.98 | 0 | 100 | -9.43 | -9.43 | -9.43 | -9.43 | -9.43 |
| Accounts Payable | 1.8 | 4.8 | 3.3 | 3.5 | 4.4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 13.13 | 26.41 | 106.17 | 16.96 | 100 | 51.3 | 51.3 | 51.3 | 51.3 | 51.3 |
| Capital Expenditure | -1.0 | -9.1 | -11.5 | -2.8 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -7.35 | -50.5 | -368.68 | -13.37 | 100 | -34.24 | -34.24 | -34.24 | -34.24 | -34.24 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -56.5 | -68.3 | -103.5 | -112.9 | -187.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -55.8 | -61.5 | -115.2 | -115.5 | -187.0 | -4.4 | .0 | .0 | .0 | .0 |
| WACC, % | 16.01 | 15.99 | 15.98 | 16.01 | 16.01 | 16 | 16 | 16 | 16 | 16 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -125 | |||||||||
| Equity Value | 121 | |||||||||
| Diluted Shares Outstanding, MM | 54 | |||||||||
| Equity Value Per Share | 2.24 |
What You Will Get
- Real FDMT Financial Data: Pre-filled with 4D Molecular Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See 4D Molecular Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Customizable Research Parameters: Adjust vital inputs such as therapeutic efficacy, market potential, and production costs.
- Instant DCF Analysis: Quickly computes intrinsic value, NPV, and other financial metrics.
- High-Precision Outcomes: Leverages 4D Molecular Therapeutics' real-world data for accurate valuation results.
- Streamlined Scenario Testing: Easily evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review 4D Molecular Therapeutics, Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions regarding (FDMT).
Why Choose This Calculator for 4D Molecular Therapeutics, Inc. (FDMT)?
- Precision: Utilizes authentic 4D Molecular Therapeutics financial data for reliable results.
- Adaptability: Crafted for users to easily experiment and adjust inputs as needed.
- Efficiency: Eliminate the complexities of creating a financial model from the ground up.
- Expert-Level: Built with the accuracy and functionality expected by industry leaders.
- Intuitive: Designed for ease of use, catering to individuals with varying levels of financial expertise.
Who Should Use This Product?
- Biotech Students: Explore advanced gene therapy techniques and apply them using real-world data.
- Researchers: Integrate cutting-edge molecular models into your studies or publications.
- Investors: Evaluate your investment strategies and analyze the market performance of 4D Molecular Therapeutics (FDMT).
- Industry Analysts: Enhance your analysis with a customizable framework for assessing biotech companies.
- Healthcare Professionals: Understand the methodologies behind the evaluation of innovative therapies like those developed by 4D Molecular Therapeutics (FDMT).
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for 4D Molecular Therapeutics, Inc. (FDMT).
- Real-World Data: 4D Molecular Therapeutics' historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Built-in analysis for profitability, efficiency, and leverage specific to 4D Molecular Therapeutics, Inc. (FDMT).
- Dashboard with Visual Outputs: Charts and tables providing clear, actionable results for informed decision-making.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.